The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise

In this work we investigate, by means of a computational stochastic model, how tumor cells with wild-type p53 gene respond to the drug Nutlin, an agent that interferes with the Mdm2-mediated p53 regulation. In particular, we show how the stochastic gene-switching controlled by p53 can explain experimental dose-response curves, i.e., the observed inter-cell variability of the cell viability under Nutlin action. The proposed model describes in some detail the regulation network of p53, including the negative feedback loop mediated by Mdm2 and the positive loop mediated by PTEN, as well as the reversible inhibition of Mdm2 caused by Nutlin binding. The fate of the individual cell is assumed to be decided by the rising of nuclear-phosphorylated p53 over a certain threshold. We also performed in silico experiments to evaluate the dose-response curve after a single drug dose delivered in mice, or after its fractionated administration. Our results suggest that dose-splitting may be ineffective at low doses and effective at high doses. This complex behavior can be due to the interplay among the existence of a threshold on the p53 level for its cell activity, the nonlinearity of the relationship between the bolus dose and the peak of active p53, and the relatively fast elimination of the drug.

[1]  Roberto Barbuti,et al.  Tumour suppression by immune system through stochastic oscillations. , 2010, Journal of theoretical biology.

[2]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[3]  Roberto Natalini,et al.  A spatial physiological model for p53 intracellular dynamics. , 2013, Journal of theoretical biology.

[4]  Jack A. Tuszynski,et al.  Stochastic and Deterministic Models of Cellular p53 Regulation , 2013, Front. Oncol..

[5]  A. Fersht,et al.  Cooperative binding of tetrameric p53 to DNA. , 2004, Journal of molecular biology.

[6]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[7]  Alberto d’Onofrio,et al.  Bounded Noises in Physics, Biology, and Engineering , 2013 .

[8]  Yan Zhao,et al.  Abstract 4529: Cellular pharmacokinetic and activity studies with the MDM2-p53 inhibitor Nutlin-3 , 2010 .

[9]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[10]  Fan Zhang,et al.  Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration , 2011, Drug Metabolism and Disposition.

[11]  Antonio Di Cristofano,et al.  Class reunion: PTEN joins the nuclear crew , 2005, Oncogene.

[12]  J. Beck,et al.  Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. , 2011, European journal of cancer.

[13]  G. Wahl,et al.  p53 regulation by post-translational modification and nuclear retention in response to diverse stresses , 1999, Oncogene.

[14]  Sachiko Iseki,et al.  Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation. , 2012, Biochemical and biophysical research communications.

[15]  Duccio Fanelli,et al.  A dynamical model of apoptosis and its role in tumor progression , 2012 .

[16]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[17]  Andrea Ciliberto,et al.  Steady States and Oscillations in the p53/Mdm2 Network , 2005, Cell cycle.

[18]  Samuel Bottani,et al.  Analysis of a minimal model for p53 oscillations. , 2007, Journal of theoretical biology.

[19]  M. Chaplain,et al.  Spatial stochastic modelling of the Hes1 gene regulatory network: intrinsic noise can explain heterogeneity in embryonic stem cell differentiation , 2013, Journal of The Royal Society Interface.

[20]  Seth Michelson,et al.  Systems Biology in Drug Discovery and Development: Young/Systems Bio in Drug Discovery , 2011 .

[21]  J. Li,et al.  MiR‐125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway , 2014, Cell proliferation.

[22]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[23]  T. Elston,et al.  Stochasticity in gene expression: from theories to phenotypes , 2005, Nature Reviews Genetics.

[24]  Masaki Mori,et al.  MicroRNA miR-125b is a prognostic marker in human colorectal cancer. , 2011, International journal of oncology.

[25]  A. Monteiro,et al.  Phosphatases in the cellular response to DNA damage , 2010, Cell Communication and Signaling.

[26]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[27]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[29]  R. Sachidanandam,et al.  A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis , 2013, Cell Death and Differentiation.

[30]  N. Monk Oscillatory Expression of Hes1, p53, and NF-κB Driven by Transcriptional Time Delays , 2003, Current Biology.

[31]  G. Wahl,et al.  Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation , 2004, The EMBO journal.

[32]  D. Tranchina,et al.  Stochastic mRNA Synthesis in Mammalian Cells , 2006, PLoS biology.

[33]  K. Sneppen,et al.  Oscillations and temporal signalling in cells , 2007, Physical biology.

[34]  G. Wahl,et al.  Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.

[35]  Roman Jaksik,et al.  Regulation of p53 by siRNA in radiation treated cells: Simulation studies , 2012, Int. J. Appl. Math. Comput. Sci..

[36]  C. Maki,et al.  Persistent p21 Expression after Nutlin-3a Removal Is Associated with Senescence-like Arrest in 4N Cells , 2010, The Journal of Biological Chemistry.

[37]  A. Gudkov,et al.  Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A , 2009, Cell cycle.

[38]  Fangyi Zhu,et al.  Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. , 2011, Cancer research.

[39]  Wei Wang,et al.  Two-phase dynamics of p53 in the DNA damage response , 2011, Proceedings of the National Academy of Sciences.

[40]  Kyoohyoung Rho,et al.  A theoretical model for p53 dynamics: Identifying optimal therapeutic strategy for its activation and stabilization , 2009, Cell cycle.

[41]  M. Groudine,et al.  Enhancers increase the probability but not the level of gene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[43]  Wei Wang,et al.  Coordination between Cell Cycle Progression and Cell Fate Decision by the p53 and E2F1 Pathways in Response to DNA Damage* , 2010, The Journal of Biological Chemistry.

[44]  Binh Vu,et al.  MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. , 2013, Cancer research.

[45]  Xuejun Jiang,et al.  MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination , 2011, The Journal of Biological Chemistry.

[46]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[47]  Baoying Huang,et al.  Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells , 2009, Molecular Cancer Research.

[48]  Jiandong Chen,et al.  MDMX regulation of p53 response to ribosomal stress , 2006, The EMBO journal.

[49]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[50]  Pier Paolo Di Fiore,et al.  The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells , 2009, Cell.

[51]  U Alon,et al.  Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Huey-Jen Lin,et al.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. , 2010, Cancer cell.

[53]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[54]  L. Jeffrey Medeiros,et al.  Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma , 2007, Clinical Cancer Research.

[55]  Baoli Hu,et al.  MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin* , 2006, Journal of Biological Chemistry.

[56]  Laurence Choulier,et al.  Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells. , 2013, Cancer letters.

[57]  Jing Zhang,et al.  Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.

[58]  B. Kholodenko Cell-signalling dynamics in time and space , 2006, Nature Reviews Molecular Cell Biology.

[59]  H. Lodish,et al.  MicroRNA-125b is a novel negative regulator of p53. , 2009, Genes & development.

[60]  Marc Sturrock,et al.  Spatio-temporal modelling of the Hes1 and p53-Mdm2 intracellular signalling pathways. , 2011, Journal of theoretical biology.

[61]  Y. E. Chen,et al.  Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth , 2013, Clinical Cancer Research.

[62]  Shiwei Yan,et al.  A unified model for studying DNA damage-induced p53–Mdm2 interaction , 2006 .

[63]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Baoying Huang,et al.  Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation , 2008, Cell cycle.

[65]  D. Gillespie Exact Stochastic Simulation of Coupled Chemical Reactions , 1977 .

[66]  Pradeep Kumar Shreenivasaiah,et al.  microRNA Regulation of Networks of Normal and Cancer Cells , 2010 .

[67]  Jun S. Song,et al.  Negative regulation of tumor suppressor p53 by microRNA miR-504. , 2010, Molecular cell.

[68]  Jean-Christophe Marine,et al.  Mdmx as an essential regulator of p53 activity. , 2005, Biochemical and biophysical research communications.

[69]  Sandeep Krishna,et al.  Stress-specific response of the p53-Mdm2 feedback loop , 2010, BMC Systems Biology.

[70]  Jun Li,et al.  A Two-Step Mechanism for Cell Fate Decision by Coordination of Nuclear and Mitochondrial p53 Activities , 2012, PloS one.

[71]  Patrick W. Lee,et al.  Biogenesis of p53 Involves Cotranslational Dimerization of Monomers and Posttranslational Dimerization of Dimers , 2002, The Journal of Biological Chemistry.

[72]  J. Acebes,et al.  Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme , 2011, PloS one.

[73]  T. Kepler,et al.  Stochasticity in transcriptional regulation: origins, consequences, and mathematical representations. , 2001, Biophysical journal.

[74]  E. Appella,et al.  Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.

[75]  D. Meek,et al.  Multisite phosphorylation and the integration of stress signals at p53. , 1998, Cellular signalling.

[76]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[77]  Alan J. Terry,et al.  Influence of the Nuclear Membrane, Active Transport, and Cell Shape on the Hes1 and p53–Mdm2 Pathways: Insights from Spatio-temporal Modelling , 2012, Bulletin of mathematical biology.

[78]  Tomasz Lipniacki,et al.  Oscillations and bistability in the stochastic model of p53 regulation. , 2008, Journal of theoretical biology.

[79]  Giancarlo Mauri,et al.  The Interplay of Intrinsic and Extrinsic Bounded Noises in Biomolecular Networks , 2012, PloS one.

[80]  Jindrich Cinatl,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. , 2009, Cancer research.

[81]  Hong Yang,et al.  Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. , 2005, Cancer research.

[82]  Alberto Gandolfi,et al.  Resistance to antitumor chemotherapy due to bounded-noise-induced transitions. , 2010, Physical review. E, Statistical, nonlinear, and soft matter physics.

[83]  E. Wang MicroRNA Systems Biology , 2007, 0712.3569.

[84]  Marek Kimmel,et al.  Single TNFα trimers mediating NF-κB activation: stochastic robustness of NF-κB signaling , 2007, BMC Bioinformatics.

[85]  John Jeremy Rice,et al.  A plausible model for the digital response of p53 to DNA damage. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[86]  T Maimets,et al.  Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells , 2008, Oncogene.

[87]  Anang A. Shelat,et al.  First Small Molecule Inhibitor of MDMX Identification and Characterization of the Cell Biology : , 2010 .

[88]  Paul Brazhnik,et al.  HAUSP-regulated switch from auto- to p53 ubiquitination by Mdm2 (in silico discovery). , 2007, Mathematical biosciences.

[89]  H. Hermeking,et al.  MicroRNAs in the p53 network: micromanagement of tumour suppression , 2012, Nature Reviews Cancer.

[90]  M. Ko,et al.  A stochastic model for gene induction. , 1991, Journal of theoretical biology.

[91]  Daniel J. Freeman,et al.  PTEN Regulates Mdm2 Expression through the P1 Promoter* , 2004, Journal of Biological Chemistry.

[92]  F S Fay,et al.  Visualization of single RNA transcripts in situ. , 1998, Science.

[93]  E. Berg Systems biology in drug discovery and development. , 2014, Drug discovery today.

[94]  Roser Mir,et al.  Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild‐type ovarian cancer cells , 2013, International journal of cancer.